Scribe Therapeutics (NASDAQ:SCTX) reported quarterly losses of $(2.62) per share which missed the analyst consensus estimate of $(1.05) by 149.52 percent. The company reported quarterly sales of $1.918 million which missed the analyst consensus estimate of $3.113 million by 38.39 percent.